10:53 AM EDT, 05/20/2024 (MT Newswires) -- NKGen Biotech ( NKGN ) said Monday its safety review committee has cleared the company's expanded SNK01 cell therapy to progress into phase 2 clinical development in Alzheimer's disease.

The phase 2trial will evaluate efficacy and further safety of SNK01 in a larger group of 30 patients with moderate Alzheimer's disease, the company said.

NKGen said its phase 1 study showed that even after only four doses, SNK01 was "very safe" and able to cross the blood brain barrier to lower amyloid, tau, and alpha-synuclein proteins, as well as neuroinflammation in a dose-responsive manner.

The company's shares were up nearly 62% in recent trading.

Price: 1.81, Change: +0.69, Percent Change: +61.70